Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia

Leukemia

Volumn 23, Issue 5, 2009, Pages 1011-1017

  Gunn, S R ^a,b   Hibbard, M K ^c   Ismail, S H ^b   Lowery Nordberg, M ^d   Mellink, C H M ^e   Bahler, D W ^f   Abruzzo, L V ^g   Enriquez, E L ^a   Gorre, M E ^a   Mohammed, M S ^a   Robetorye, R S ^b  

^a Combimatrix Molecular Diagnostics ^*  (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c Laboratory Department   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CELL ADHESION MOLECULE; CELL PROTEIN; PROMYELOCYTIC LEUKEMIA ZINC FINGER PROTEIN; PROTEIN TSLC1; TUMOR SUPPRESSOR IN LUNG CNCER 1; UNCLASSIFIED DRUG; ZESTE WHITE 10 HOMOLOG; ZINC FINGER PROTEIN;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 16P; CHROMOSOME 3P; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME LOSS; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC ACCURACY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENOME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 67349277730     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.393     Document Type: Article

References (32)

1. Döhner H, Stilgenbauer S, Benner A, Ceupolt E, Kober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI-WG) 1996 guidelines. Blood 2008; 111: 5446-5456.
3. Zenz T, Döhner H, Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 439-453.
4. Glassman AB, Hayes KJ. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2005; 158: 88-91.
5. Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ et al. Prognostic subgroups in B-cell-chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720-724.
6. Kay NE, O'Brien SM, Pettit AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007; 21: 1885-1891.
7. Dickinson JD, Smith LM, Sanger WG, Zhou G, Townley P, Lynch JC et al Unique gene expression and clinical characteristics with the 11q23 deletion in chronic lymphocytic leukemia. Br J Haematol 2005; 128: 460-461.
8. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47: 1738-1746.
9. Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc Nad Acad Sci USA 2004; 101 1039-1044.
10. Patel A, Kang S-H, Lennon PA, Li YF, Rao PN, Abruzzo L et al. Validation of a targeted DNA microarray for clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia. Am J Hematol 2008; 83: 540-546.
11. Gunn SR, Mohammed MS, Mellink CHM, Abruzzo LV, Robetorye RS. The HemeScan test for genomic prognostic marker assessment in chronic lymphocytic leukemia. Expert Opin Med Diagn 2008; 2: 731-740.
12. Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 2008; 10: 442-451.
13. Sargent R, Jones D, Abruzzo LV, Yao H, Bonderover J, Cisneros M et al Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn 2009; 11: 25-34.
14. Higgins RA, Gunn SR, Robetorye RS. Clinical application of arraybased comparative genomic hybridization arrays for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. Mol Diagn Ther 2008; 12: 271-280.
15. Stilgenbauer S, Liebisch P, James MR, Schroder M, Schlegelberger B, Fischer K et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome band 11q22.3-q23.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 1996; 93 11837-11841.
16. Eclache V, Caulet-Maugendre S, Poirel HA, Djemai M, Robert J, Lejeune F et al. Cryptic deletion involving the ATM locus at 11q22.3-q23.1 in B-cell chronic lymphocytic leukemia and selated disorders. Cancer Genet Cytogenet 2004; 152: 72-76.
17. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D et al. Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberration associated with unmutated VH, resistance to therapy and short survival. Haematology 2007; 92: 1242-1245.
18. Vallee RB, Varma D, Dujardin DL. ZW10 function in mitotic checkpoint control, dynein targeting and membrane trafficking: Is dynein the unifying theme? Cell Cycle 2006; 5: 2447-2451.
19. Gao K, Lockwood WW, Li J, Lam W, Li G. Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells. Int J Oncol 2008; 32: 1343-1349.
20. Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S et al. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol 1998; 18: 5533-5545.
21. Yeyati PL, Shaknovich R, Boterashvili, S, Li J, Ball HJ, Waxman S et al. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999; 18: 925-934.
22. McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM et al. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 2003; 23: 9375-9388.
23. Nowacki S, Skowron M, Oberthuer A, Fagin A, Voth H, Brors B et al. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Oncogene 2008; 27: 3329-3338.
24. Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, Murakami Y et al. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res 2006; 66: 9385-9392.
25. Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T et al. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 2002; 93: 605-609.
26. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, MarkisRitzinger EM et al. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 2007; 103 283-291.
27. Goto A, Niki T, Chi-Pin L, Matsubara D, Murakami Y, Funata N et al Loss of TSLC1 expression in lung adenocarcinoma: Relationships with histological subtypes, sex and prognostic significance. Cancer Sci 2005; 96; 480-486.
28. Houshmandi SS, Surace El, Zhang HB, Fuller GN, Gutmann DH. Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor. Neurology 2006; 67: 1863-1866.
29. Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV et al. Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. Cancer Biol Ther 2002; 1: 293-296.
30. Allinen M, Peri L, Kujala S, Lahti-Domenici J, Outila K, Karppinen SM et al. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: Indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 2002; 34: 384-389.
31. Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G et al. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res 2003; 63: 6320-6326.
32. Honda T, Tamura G, Waki T, Jin Z, Sato K, Motoyama T et al. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 2002; 93: 857-860.